The University of Colorado Cancer Center (UCCC) requests continued support for participation in the Southwest Oncology Group (SWOG) as a member institution. The UCCC mission is the reduction of cancer incidence and mortality through laboratory and clinical research. Participation in SWOG has been an integral part of this mission. Investigators from the UCCC continue to contribute to the administrative, educational and scientific functions of SWOG. Drs. Scott Bearman (Principal Investigator), E. David Crawford, and Laurie Gaspar sit on the Board of Governors, SWOG's executive committee. UCCC SWOG members chair the Genitourinary (E.D. Crawford) and Lung Pathobiology (Wilbur Franklin) Committees. Dr. Scott Lucia serves as the director of the Diagnostic Center for the Prostate Cancer Prevention Trial (PCPT). Dr. Lucia is also a member of the steering committees for PCPT and Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Michele Basche was selected as a SWOG Young Investigator in 2002. UCCC members are coordinators or co-coordinators of 11% of active SWOG protocols activated during the 1997-2002 grant period. In addition, institutional pilot studies conducted at the UCCC have been brought to the Group in the form of prospective randomized trials and groupwide Phase II studies. UCCC investigators make important contributions to the Blood and Marrow Transplantation, Breast, Lung, Radiation Therapy and GU Committees. New faculty members are expected to increase participation further, particularly in the Gastrointestinal (S. Gail Eckhardt and Michele Basche) and Lymphoma (John Sweetenham) Committees. We are proud of our contributions to the Southwest Oncology Group and are committed to its mission. We expect our Southwest Oncology Group activities to increase in the next grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA042777-19
Application #
7049457
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-01-21
Project End
2006-12-31
Budget Start
2006-04-13
Budget End
2006-12-31
Support Year
19
Fiscal Year
2006
Total Cost
$164,202
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Advani, Anjali S; McDonough, Shannon; Copelan, Edward et al. (2014) SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 167:233-7
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
NSCLC Meta-analysis Collaborative Group (2014) Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383:1561-71

Showing the most recent 10 out of 222 publications